Wall Street brokerages expect Neuronetics Inc (NASDAQ:STIM) to report ($0.36) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Neuronetics’ earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.37). The firm is expected to report its next earnings results on Tuesday, February 5th.

According to Zacks, analysts expect that Neuronetics will report full-year earnings of ($1.89) per share for the current financial year, with EPS estimates ranging from ($2.11) to ($1.66). For the next year, analysts expect that the firm will post earnings of ($1.24) per share, with EPS estimates ranging from ($1.29) to ($1.18). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that follow Neuronetics.

Neuronetics (NASDAQ:STIM) last announced its earnings results on Tuesday, November 6th. The company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.11. The firm had revenue of $13.74 million during the quarter, compared to analysts’ expectations of $12.68 million.

Several brokerages have recently weighed in on STIM. BTIG Research reissued a “buy” rating and issued a $33.00 target price on shares of Neuronetics in a research note on Wednesday, November 7th. JMP Securities increased their target price on shares of Neuronetics from $36.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, August 15th. Zacks Investment Research raised shares of Neuronetics from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a research note on Saturday, November 10th. Finally, Canaccord Genuity increased their target price on shares of Neuronetics from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, August 15th. Six analysts have rated the stock with a buy rating, Neuronetics presently has an average rating of “Buy” and a consensus target price of $34.50.

Shares of STIM traded up $0.07 during midday trading on Monday, hitting $18.61. The stock had a trading volume of 3,915 shares, compared to its average volume of 140,611. Neuronetics has a 1 year low of $15.40 and a 1 year high of $39.39. The company has a debt-to-equity ratio of 0.33, a current ratio of 7.63 and a quick ratio of 7.46.

Several hedge funds and other institutional investors have recently bought and sold shares of STIM. Massachusetts Financial Services Co. MA bought a new position in shares of Neuronetics in the second quarter worth about $2,661,000. TD Asset Management Inc. bought a new position in shares of Neuronetics in the second quarter worth about $329,000. Wells Fargo & Company MN bought a new position in shares of Neuronetics in the second quarter worth about $7,734,000. Victory Capital Management Inc. bought a new position in shares of Neuronetics in the second quarter worth about $133,000. Finally, Jennison Associates LLC bought a new position in shares of Neuronetics in the second quarter worth about $8,642,000. Hedge funds and other institutional investors own 69.16% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.

Featured Article: What are municipal bonds?

Get a free copy of the Zacks research report on Neuronetics (STIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.